Palmitoyl Tripeptide-5

Palmitoyl Tripeptide-5 is a lipopeptide composed of the tripeptide Lys-Val-Lys (KVK) conjugated to palmitic acid, marketed under the trade name SYN-COLL. It was developed as a synthetic mimic of thrombospondin-1 (TSP-1) to activate the TGF-β pathway and stimulate endogenous collagen synthesis. It is a widely adopted anti-aging active in premium serums and moisturizers, valued for its dual collagen-synthesis and MMP-inhibition activity.

Palmitoyl Tripeptide-5 mimics the TSP-1 sequence that activates latent transforming growth factor-beta (TGF-β). By binding to the latency-associated peptide region of inactive TGF-β, the tripeptide induces release of the active growth factor, which then signals dermal fibroblasts via Smad2/3 phosphorylation to upregulate type I and III collagen synthesis. Simultaneously, Palmitoyl Tripeptide-5 inhibits matrix metalloproteinases (MMP-1, MMP-2, MMP-9) that degrade existing collagen, providing a dual protective and regenerative action. The palmitoyl lipid chain enhances penetration through the stratum corneum and increases residence time in the dermis by anchoring the peptide to membrane phospholipids.

Manufacturer-sponsored clinical studies (Lipotec / Lubrizol) report measurable reductions in wrinkle depth and improvements in skin firmness after 28–56 days of twice-daily application versus placebo. In vitro fibroblast assays demonstrate statistically significant increases in collagen I and III mRNA expression. A 2025 PMC review of anti-aging peptides cites Palmitoyl Tripeptide-5 among well-characterized matrikine-class cosmetic actives with consistent in vitro evidence. Independent peer-reviewed clinical trials remain limited as of 2026.

Peptides commonly paired with Palmitoyl Tripeptide-5 for synergistic effects.